Prescriber Checklist Tool

Evusheld™

UTAH DEPARTMENT OF HEALTH

Updated 2/28/2022

Patient eligibility

The FDA has issued an emergency use authorization (EUA) for tixagevimab co-packaged with cilgavimab (Evusheld) for **pre-exposure prophylaxis** of COVID-19 in the following individuals:

- ❑ Aged ≥12 years and weighing at least 40 kg, and
- ❑ Who are not currently infected with SARS-CoV-2 and have not had a known recent exposure to an individual infected with SARS-CoV-2, and
- ❑ Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments* and may not mount an adequate immune response to COVID-19 vaccination, or
- ❑ For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).
- ❑ For whom Evusheld is not being used for treatment or post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.

Requirements

Requirements prior to administration of Evusheld under EUA

- ❑ Healthcare facilities and healthcare providers will ensure that they are aware of the Letter of Authorization, and the terms therein, and that the authorized Fact Sheets are made available to healthcare providers and to patients, parents, and caregivers, respectively, through appropriate means, prior to administration of Evusheld.
- ❑ Consider the risks and benefits prior to initiating Evusheld in individuals at high risk for cardiovascular events (see section 6.1 of the Evusheld Fact Sheet for Healthcare Providers).

Administration

Important information regarding the administration of Evusheld

- ❑ Evushled is available as an individual single-dose vial of tixagevimab co-packaged with a single-dose vial of cilgavimab for intramuscular (IM) administration.
- ❑ The two components of Evusheld are administered consecutively, preferably one in each of the gluteal muscles Evusheld may be redosed every 6 months.
- ❑ If an individual has been vaccinated with the COVID-19 vaccine, administer Evusheld at least two weeks after vaccination.
- ❑ Given its IM route of administration, Evusheld should be given with caution to individuals with thrombocytopenia or any coagulation disorder.
- ❑ Clinically monitor individuals after injections for at least 1 hour due to a risk of hypersensitivity with Evusheld.

Important notice

The prescribing healthcare provider and/or designee must report all medication errors and serious adverse events potentially related to Evusheld within 7 calendar days from the healthcare provider's awareness of the event to FDA MedWatch.

*Per the EUA, medical conditions or treatments that may result in moderate to severe immune compromise and inadequate immune response to COVID-19 vaccination include but are not limited to:

- Active treatment for solid tumor and hematologic conditions.
- Receipt of solid-organ transplant and taking immunosuppressive therapy.
- Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy).
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).
- Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestation of symptomatic HIV).
- Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutics agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents).